Pfizer launches first human trial of experimental eczema treatment

NCT ID NCT06564389

Recruiting now Symptom relief Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study tests an experimental drug called PF-07832837 in healthy adults and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug might improve eczema symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS HEALTHY PARTICIPANTS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Anaheim Clinical Trials, LLC
RECRUITING

Anaheim, California, 92801, United States
Miami Dermatology and Laser Research
RECRUITING

Miami, Florida, 33133, United States
Paddington Testing Company
RECRUITING

Philadelphia, Pennsylvania, 19103, United States
Revival Research Institute, LLC
RECRUITING

Troy, Michigan, 48084, United States
TCR Medical Corporation
RECRUITING

San Diego, California, 92123, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.